Compare LSF & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSF | XLO |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0M | 56.9M |
| IPO Year | 2020 | 2021 |
| Metric | LSF | XLO |
|---|---|---|
| Price | $4.71 | $9.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 39.5K | 23.3K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,889,286.00 | $43,766,000.00 |
| Revenue This Year | $90.82 | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | $39.82 | ★ N/A |
| Revenue Growth | 15.23 | ★ 589.88 |
| 52 Week Low | $1.96 | $0.46 |
| 52 Week High | $6.50 | $9.89 |
| Indicator | LSF | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 62.51 | 55.69 |
| Support Level | $2.23 | $7.47 |
| Resistance Level | $5.11 | $9.22 |
| Average True Range (ATR) | 0.41 | 0.38 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 89.80 | 54.04 |
Laird Superfood Inc is engaged in the development and marketing of food and beverage products focused on health and wellness. The company's product portfolio includes coffee creamers, coffee, tea, hot chocolate, hydration and beverage enhancement products, and snacks, made using natural and functional ingredients.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.